NLS Pharmaceutics AG (NLSPW)
USD 0.01
(9.8%)
USD 0.01
(9.8%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -9.68 Million | -13.87 Million | -14.93 Million | -729.38 Thousand | -190 Thousand | -2.73 Million |
| Net Income | -12.17 Million | -16.49 Million | -11.94 Million | -2.86 Million | -5.44 Million | -5.14 Million |
| Depreciation & Amortization | 11.4 Thousand | 11.4 Thousand | 10.05 Thousand | 72.18 Million | - | - |
| Deferred income taxes | - | 613.42 Thousand | - | - | - | - |
| Stock-based compensation | 164.9 Thousand | 22.73 Thousand | - | - | - | - |
| Change in working capital | 2.25 Million | 1.62 Million | -3.16 Million | 2.06 Million | 4.11 Million | 667.75 Thousand |
| Other non-cash items | -2.01 Million | 364.64 Thousand | 166.5 Thousand | -72.12 Million | 1.14 Million | 1.74 Million |
| Investing Cash Flow | - | -3.51 Million | -39.56 Thousand | 225.63 Thousand | -217.25 Thousand | - |
| Investments in PPE | -4.00 | - | -39.56 Thousand | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 1.63 Million | 17.39 Million | 20.33 Million | 503.52 Thousand | 407.47 Thousand | 557.92 Thousand |
| Debt repayment | -1.63 Million | -704.16 Thousand | -2.1 Million | -1.19 Million | -667.69 Thousand | -557.92 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 18.1 Million | 18.89 Million | - | - | - |
| Other Financing Activities | 1633.75 | 17.39 Thousand | 3.54 Million | 1.69 Million | 1.07 Million | 1.11 Million |
| Accounts receivables | - | - | -21.8 Thousand | -13.48 Thousand | 1000.00 | -41.1 Thousand |
| Accounts payables | 2.26 Million | 636.26 Thousand | -2.26 Million | 1.49 Million | 1.37 Million | 565.85 Thousand |
| Inventory | - | - | - | - | - | 41.1 Thousand |
| Other working capital | -8535.00 | 990.54 Thousand | -875.26 Thousand | 580.47 Thousand | 2.73 Million | 101.9 Thousand |
| Cash at beginning of period | 8.94 Million | 5.43 Million | 93.71 Thousand | 220.26 Thousand | 6678.00 | 2.18 Million |
| Cash at end of period | 897.68 Thousand | 8.94 Million | 5.43 Million | 93.71 Thousand | 220.26 Thousand | 6678.00 |
| Capital Expenditure | -4.00 | - | -39.56 Thousand | - | - | - |
| Effect of forex changes on cash | - | -0.10 | -24.74 | 99.31 | -3.88 | -1369.00 |
| Net cash flow / Change in cash | -8.05 Million | 3.51 Million | 5.33 Million | -126.55 Thousand | 213.58 Thousand | -2.17 Million |
| Free Cash Flow | -9.68 Million | -13.87 Million | -14.97 Million | -729.38 Thousand | -190 Thousand | -2.73 Million |
| Breakdown | 2024 Q2 | 2023 FY | 2023 Q4 | 2023 Q2 | 2022 FY | 2022 Q4 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -2.03 Million | -12.17 Million | -4559.29 | -7.61 Million | -16.49 Million | -7.85 Million |
| Depreciation & Amortization | 5704.00 | 11.4 Thousand | 5.70 | 5704.00 | 11.4 Thousand | 5704.00 |
| Deferred income taxes | - | - | - | 728.28 Thousand | 613.42 Thousand | -160.01 Thousand |
| Stock-based compensation | - | 164.9 Thousand | 104.39 | 60.52 | 22.73 Thousand | 22.73 |
| Change in working capital | 400.21 Thousand | 2.25 Million | 465.79 | 265.42 Thousand | 1.62 Million | 646.02 Thousand |
| Other non-cash items | 99.42 Thousand | -2.01 Million | 1595.47 | -683.25 Thousand | 364.64 Thousand | 1.14 Million |
| Investing Cash Flow | - | - | - | - | -3.51 Million | -7.59 Million |
| Investments in PPE | -2.00 | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 1.18 Million | 1.63 Million | 1633.75 | - | 17.39 Million | 13.8 Million |
| Debt repayment | -194.71 Thousand | -1.63 Million | - | - | -704.16 Thousand | -354.33 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 1.38 Million | - | - | - | 18.1 Million | 14.16 Million |
| Other Financing Activities | - | 1633.75 | 1633.75 | - | 17.39 Thousand | 13.8 Thousand |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | -49.24 Thousand | 2.26 Million | 1.52 Million | 739.74 Thousand | 636.26 Thousand | -148.58 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 449.46 Thousand | -8535.00 | 465.79 | -474.32 Thousand | 990.54 Thousand | 794.6 Thousand |
| Cash at beginning of period | 897.68 Thousand | 8.94 Million | 1651.45 | 8.94 Million | 5.43 Million | 1.35 Million |
| Cash at end of period | 552.75 Thousand | 897.68 Thousand | 897.68 Thousand | 1.65 Million | 8.94 Million | 8.94 Million |
| Capital Expenditure | -2.00 | - | - | - | - | - |
| Effect of forex changes on cash | - | - | 0.42 | -0.42 | -0.10 | -0.41 |
| Net cash flow / Change in cash | -344.92 Thousand | -8.05 Million | 896.02 Thousand | -7.29 Million | 3.51 Million | 7.59 Million |
| Free Cash Flow | -1.53 Million | -9.68 Million | -2387.93 | -7.29 Million | -13.87 Million | -6.21 Million |
CPH
BDM
FBYDW
H2G
6866
GNTX